Form 4: Evommune Executive Executes Stock Option Exercise

Chief Business & Legal Officer Gregory S. Moss exercised options and sold 14,223 shares of Evommune, Inc. common stock.

Summary

• Gregory S. Moss, Chief Business & Legal Officer of Evommune, Inc., exercised options to acquire 14,223 shares of common stock at a price of $1.71 per share.
• Following the acquisition, the reporting person sold the same 14,223 shares at a weighted average price of $22.83 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2026.
• The sales occurred in a price range between $22.50 and $23.42 per share.
• Post-transaction, the reporting person maintains direct ownership of 60,835 shares and indirect ownership of 3,175 shares held in a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents a standard exercise of executive compensation.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Future share price volatility could impact the value of remaining holdings held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and is generally viewed as neutral by the market, provided it does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential allegations of insider trading.
• The scale of the transaction is relatively small compared to the total outstanding shares of a typical biotechnology firm.

Related Party Transactions

• The reporting person holds 3,175 shares through a family trust for which he serves as trustee.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was executed through a pre-planned trading arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Evommune, EVMN, Insider Trading, Form 4, Stock Options, Rule 10b5-1